Biopharmaceutical company Scancell Holdings plc (AIM: SCLP), a developer of novel oncology immunotherapies, revealed on Wednesday that it has granted a major international biotechnology company exclusivity to evaluate its investigational anti-glycan monoclonal antibody.
This antibody, part of Scancell's GlyMab platform, will be assessed for the development of novel therapeutic products. The agreement includes a USD1m exclusivity payment due within 30 days and lasts for seven months.
Scancell's anti-glycan monoclonal antibody is one of five developed using its proprietary GlyMab platform, which targets sugar motifs on cancer cells rather than proteins. This innovative approach allows the identification and development of multiple monoclonal antibodies against glycan targets, with a robust portfolio of patents supporting the technology.
The company is advancing a pipeline of differentiated anti-cancer monoclonal antibodies, including GlyMab and AvidiMab. The company leverages its proprietary research on the human adaptive immune system to create novel therapies for cancer and infectious diseases, utilising four technology platforms: Moditope and ImmunoBody for vaccines, along with GlyMab and AvidiMab for antibodies.
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
SCG Cell Therapy's SCG142 IND application receives US FDA approval
EDX Medical to distribute cResponse cancer assay in UK and Nordics
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib